Clinical trial
REVLIMID® Drug Use Examination
NCT02556905 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- REVLIMID® Drug Use Examination
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 9, 2011
- Completion date
- November 30, 2016
- Enrollment
- 624 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.